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Preeclampsia (PE) is hypertensionwith proteinuria that develops during pregnancy and affects at least 5% of pregnancies.The Effect
of Folic Acid Supplementation in Pregnancy on Preeclampsia: the Folic Acid Clinical Trial (FACT) aims to recruit 3,656 high risk
women to evaluate a new prevention strategy for PE: supplementation of folic acid throughout pregnancy. Pregnant women with
increased risk of developing PE presenting to a trial participating center between 80/7 and 166/7 weeks of gestation are randomized
in a 1 : 1 ratio to folic acid 4.0mg or placebo after written consent is obtained. Intent-to-treat population will be analyzed.The FACT
study was funded by the Canadian Institutes of Health Research in 2009, and regulatory approval fromHealth Canada was obtained
in 2010. A web-based randomization system and electronic data collection system provide the platform for participating centers to
randomize their eligible participants and enter data in real time. To date we have twenty participating Canadian centers, of which
eighteen are actively recruiting, and seven participating Australian centers, of which two are actively recruiting. Recruitment in
Argentina, UK, Netherlands, Brazil, West Indies, and United States is expected to begin by the second or third quarter of 2013.This
trial is registered with NCT01355159.
1. Introduction
Preeclampsia (PE) is a leading cause ofmaternal and neonatal
morbidity andmortality [1, 2]. It accounts for about one-third
of maternal deaths, ranking second amongst causes of preg-
nancy associated deaths in industrialized countries [3, 4]. A
3- to 25-fold increased risk of abruptio placentae, thrombocy-
topenia, disseminated intravascular coagulation, pulmonary
edema, and aspiration pneumonia [5] is associated with PE.
Furthermore, women with a history of PE continue to be at
increased risk for future cardiovascular events [6, 7]. Since
delivery is the only known cure, PE is a leading cause of
indicated preterm delivery [8]. PE accounts for 25% of very
low birth weight infants [9], and as many as 60% of these
infants suffer from learning disabilities and are associated
with a low IQ [10]. PEmay also increase the risk of cardiovas-
cular disease in the offspring through “fetal origins of adult
diseases” [11, 12].
There is strong evidence from both animal and human
studies, including our own large cohort studies [13, 14] to
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support the hypothesized protective effect of folic acid on PE.
We conducted a thorough search of literature in 2008 (MED-
LINE (1966—September 2013), EMBASE (1980–2013), and
Cochrane Central Register of Controlled Trials (Cochrane
Library 2013), using a combination of the following medical
subject heading (MeSH) terms: folic acid, folate, multiple
vitamin, multivitamin, gestational hypertension or hyper-
tension in pregnancy or pregnancy induced hypertension,
and PE. We identified ten relevant studies, including six
cohort studies, two case-control studies, and two randomized
controlled trials (RCTs).Three earlier cohort studies assessed
the effect of folic acid containing multivitamins (including
folic acid) and gestational hypertension (including PE) [13,
15, 16], all showed a protective effect of folic acid supple-
mentation on PE. A recent large cohort study from Denmark
also showed that regular use of folic acid in pregnancy was
related to a reduced risk of PE among normal-weight women
[17]. However, two recent studies in China [18] and Holland
[19] failed to find an effect of folic acid supplementation on
PE or gestational hypertension. A case-control study (𝑛 = 231
patients) in Syria did not report the crude and adjusted odds
ratio (OR) [20]. Based on available data we calculated the
OR as being 0.14 (95% CI = 0.06–0.31), showing a strong
protective effect of folic acid supplementation. In a large case-
control study in Hungary involving 1,017 pregnant women
with medically recorded PE and 37,134 pregnant women
without PE, Ba´nhidy et al. found that there was a lower risk
of preterm birth of newborn infants born to pregnant women
with early onset PE after folic acid supplementation from
early pregnancy [21]. In a reanalysis of randomized controlled
trial (𝑛 = 2,928 patients), the adjusted odds ratio (OR)
was 0.46 (95% CI = 0.20–1.05) for the 0.2 g/day folic acid
supplementation group and 0.59 (95% CI = 0.26–1.32) for the
5.0 g/day folic acid supplementation group [22].
Merchant et al. conducted a randomized trial to evaluate
the effect of multivitamin (20mg thiamine, 20mg riboflavin,
25mg B-6, 50microg B-12, 500mg C, 30mg E, and 0.8mg
folic acid) and vitamin A supplements (30mg beta-carotene
plus 5000 IU preformed vitamin A) in relation to hyperten-
sion in pregnancy (systolic blood pressure ≥140mmHg or
diastolic blood pressure ≥90mmHg at any time during preg-
nancy) in 955 HIV-positive pregnant Tanzanian women [23].
They found that women who received multivitamins were
38% less likely to develop hypertension during pregnancy
than those who received placebo (relative risk (RR) = 0.62,
95% CI = 0.40–0.94), while no such effect was found in
women who received vitamin A (RR = 1.00, 95% CI = 0.66–
1.51).The result of this RCT inHIV-positive patientswith folic
acid as a cointervention for gestational hypertension (includ-
ing PE) was quite consistent with findings from observational
studies.
In a historical cohort study, we compared the occur-
rence of PE between pregnant women exposed to folic acid
antagonists and nonexposed women (matched by year of
childbirth, type of institute at birth, and mother’s residence
(postal code), using the 1980 to 2000 Canadian province of
Saskatchewan databases. The risks of PE (adjusted OR 1.52,
95% confidence interval (95% CI): 1.39, 1.66) and severe PE
(OR: 1.77, 95% CI: 1.38, 2.28) were increased in mothers with
folic acid antagonist exposure [14]. Supplementary analyses
by tight matching with propensity scores restricting study
participants to first and second trimester exposure and to
specific categories of folic acid antagonists yielded similar
results. Folic acid antagonists include a broad spectrum of
drugs with a common mechanism of depleting maternal
folate. Findings from the effect of maternal exposure to folic
acid antagonists on the increased risk of PE add to the weight
of evidence that folic acid supplementation may decrease the
risk of PE.
As this review suggested, while earlier studies showed
protective effect of folic acid on reduced risk of PE, some
recent studies failed to find such an effect. The problem in
recent studies was that nonsupplementation was rare (less
than 5% in most recent studies) so that selection bias/con-
founding becomes difficult to control. That is why an RCT
is needed to sort things out. Another issue from studies by
Bodnar et al. [15] and Catov et al. [17] was that they found
a beneficial effect of folic acid in lean women or normal-
weight women only. We believe that this is caused by a dose
issue: in the Bodnar and Catov studies most women had
supplementation of 0.4mg per day, and we proposed a dose
of 4mg per day in our FACT trial. Because of the potential
genetic and metabolic defects, women with increased risk
may need a higher dose. A recent study byKeating et al. found
that folate uptake was decreased by amphetamine, atenolol,
ethanol, ecstasy, glucose, labetalol, nicotine, and tetrahydro-
cannabinol [24]. Moreover, many of these drugs/substances
were cytotoxic, and they differentially modulated the mRNA
expression of folate placental transport systems. In our birth
cohort study, we observed a dose-response relationship in
high risk women (Table 1).
Before initiation of the FACT study, we cautiously
assessed the potential risk of daily supplementation with
4.0mg folic acid during pregnancy (for a duration of about
6 months) from the following four aspects: (1) short-term
effects, (2) long-term effects, (3) existing policy on folic acid
supplementation, and (4) health care provider support in
the obstetrical community through a survey of high risk
obstetricians in the country.
(1) Short-Term Effects. No adverse outcomes were observed
in women who took very high doses of folic acid in suicide
attempts [25]. No short-term adverse outcome associated
with folic acid supplementation in pregnancy at the recom-
mended dosage has been reported. In the proposed study,
most of the study visits for study participants will be inte-
grated with their routine prenatal care services. The physical
and emotional burden to the participants in the proposed
study is small.
(2) Long-Term Effects. A hypothesis found in the literature
suggested that because folic acid is an essential coenzyme in
purine and thymine nucleotide biosynthesis and hence DNA
and RNA metabolism, it may stimulate initiation or pro-
motion of cancers such as colorectal cancer. Findings from
animal experiments and human studies of the relationship
between folic acid supplementation and colorectal cancer
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Table 1: Dose-response relationship between folic acid supplemen-
tation and PE in high risk∗ women, OaK birth cohort study, October
2002 to December 2005.
Dose of folic
acid (mg) No. of subjects No. (%) PE ORs and 95% CIs
∗∗
0 33 9 (27.27) Reference
0.1–0.9 11 1 (9.09) 0.74 (0.06, 8.88)
1.0 186 17 (9.14) 0.32 (0.10, 1.02)
1.1–1.9 18 2 (11.11) 0.24 (0.03, 1.90)
≥2.0 34 1 (2.94) 0.08 (0.01, 0.80)
∗High risk in this analysis included chronic hypertension, type 1 and type 2
diabetes, history of PE, and multiple gestation; ∗∗𝑃 < 0.05 for trend test.
were controversial, with some studies showing a protective
effect while other studies showing a potential causative effect
[26–28]. A recent meta-analysis of 10 RCTs reporting overall
cancer incidence (𝑁 = 38, 233) gave an RR of developing
cancer in patients randomised to folic acid supplements of
1.07 (95% CI = 1.00–1.14) compared to controls [29]. Meta-
analyses of six RCTs reporting prostate cancer incidence
showed an RR of prostate cancer of 1.24 (95% CI = 1.03–
1.49) for the men receiving folic acid compared to controls,
while no significant difference in cancer incidence was shown
between groups receiving folic acid and placebo/control
group, for any other cancer type [29]. Charles et al. followed
up participants from a clinical trial of folic acid supplemen-
tation in pregnancy and found a nonsignificant increase in
the risk of breast cancer deaths in the two supplementation
groups (0.2 and 5.0mg folic acid/d) as comparedwith placebo
group [30].This report is short and carries little description of
the study population and researchmethodology.The number
of deaths was small, the confidence intervals were wide, and
the authors had no prespecified hypothesis that taking folic
acid supplementation in pregnancy would increase the risk
of cancer [30]. In the accompanying commentary, Oakley
and Mandel suggested that the most likely explanation for
the reported association was chance [31]. On the contrary,
a number of other studies found that folic acid supple-
mentation was associated with lower risk of breast cancer
[31, 32]. Several more recent studies generated even more
controversial results. Ebbing et al. [33] conducted a com-
bined analysis and extended followup of participants from 2
randomized, double-blind, placebo-controlled clinical trials
(a total of 6837 patients with ischemic heart disease). After
a median of 39 months of treatment and an additional 38
months of posttrial observational followup, 341 participants
(10.0%) who received folic acid plus vitamin B(12) versus
288 participants (8.4%) who did not receive such treatment
were diagnosed with cancer (hazard ratio (HR) = 1.21; 95%
confidence interval (CI) = 1.03–1.41; 𝑃 = .02) [33]. On the
other hand, in a large double-blind randomized controlled
trial of 12064 survivors of myocardial infarction in secondary
care hospitals in the United Kingdom between 1998 and
2008, the SEARCH Collaborative Group failed to find such
an association: 678 incident cancers (11.2%) were detected in
the trial arm versus 639 cases (10.6%) in the placebo arm
[34]. The dose (2mg folic acid plus 1mg vitamin B(12) daily)
was higher and the intervention was longer (6.7 years) in
the SEARCH Collaborative Group study [34] versus 0.8mg
folic acid plus 0.4mg vitamin B(12) daily and 3.2 years in
the Ebbing study [33] matching placebo. Interventions in
the Ebbing study were also complicated, with oral treatment
with folic acid (0.8mg/d) plus vitamin B(12) (0.4mg/d) and
vitamin B(6) (40mg/d) (𝑛 = 1708); folic acid (0.8mg/d)
plus vitamin B(12) (0.4mg/d) (𝑛 = 1703); vitamin B(6)
alone (40mg/d) (𝑛 = 1705); or placebo (𝑛 = 1721) [33].
Baggott et al. conducted a meta-analysis involving 6 trials
(26385 patients) and found an increased cancer incidence in
the folic acid-supplemented groups than the nonfolic acid-
supplemented groups (relative risk = 1.21 [95% confidence
interval: 1.05–1.39]) [35]. On the other hand, Clarke et al.
conducted a meta-analysis of 8 large, randomized, placebo-
controlled trials of folic acid supplementation involving 37485
individuals at increased risk of cardiovascular disease but
did not find an increased risk of cancer: rate ratios (95%
confidence intervals) were 1.05 (0.98–1.13) for overall cancer
incidence, 1.00 (0.85–1.18) for cancer mortality, and 1.02
(0.97–1.08) for all-cause mortality [36]. One of the major
differences between the Baggott study and the Clarke study
was that Clarke et al. [36] excluded two small trials on 1955
patients with a history of colorectal adenoma while Baggott
et al. included them [35].
The effect of long-term folic acid supplementation for
cancer prevention (usually multiyears) may be quite different
from the effect of short-term folic acid supplementation for
PE prevention (usually a few months).
(3) Existing Policies. The proposed 4.0mg folic acid supple-
mentation in the trial armhas been recommended forwomen
with a previous pregnancy complicated by NTDs by the
federal government of Canada [37]. The recent recommen-
dations by the Society for Obstetricians and Gynecologists
of Canada (SOGC) are even more liberal in terms of dosage
(5.0mg instead of 4.0mg) and target population (including
women with other risk profiles such as epilepsy or family
history or high risk ethnic group or women without obvious
increased risk but with poor compliance to life-style changes
for healthy pregnancy) for high dose supplementation [38].
(4) Health Care Provider Support. We surveyed 16 perinatol-
ogists (high risk obstetricians) in the country, and 15 of them
expressed no concern of safety issue related to the trial dosage
of folic acid supplementation.
In summary, our careful and thorough assessment con-
cludes that the current data does not justify major concern of
the risk of folic acid supplementation during pregnancy, and
overall, the risk to benefit ratio favors conducting the trial.
2. Methods
This trial has been registered at http://www.controlled-
trials.com/ Registration #: ISRCTN23781770 and http://www
.clinicaltrials.gov/ Registration #: NCT01355159.
This trial has been approved by The Ottawa Hospital
Research Ethics Board, protocol number 2009-107-01H.
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3. The Intervention
The intervention of the FACT study is daily supplementation
of 4.0mg of folic acid from randomization until delivery of
the infant. Our previous study found that about 90%pregnant
women took 1.0mg folic acid or multivitamins containing
1.0mg folic acid on daily basis [13].This dose of folic acid was
associated with reduced risk of PE in the general population
[13]. The preliminary analysis of our OaK birth cohort data
demonstrated a clear dose-response relationship between
folic acid supplementation and PE risk in women with addi-
tional identified risk factors (Table 1). Due to the placental,
endothelial, and metabolic defects (including those of folate
metabolism) leading to increased risk of developing PE, a
high dose of folic acid supplementation may be required. In
our birth cohort data, the limited number of women with
a supplementation of >2.0mg prevented us from further
grouping them into higher dose groups; however, there is
likely a continued linear relationship between folic acid dose
and reduced PE risk at doses >2.0mg. We thus propose a
4.0mg folic acid for the trial. Women who are taking up to
1.1mg folic acid are eligible for the trial, and since we will not
ask the women to change their practice; the total dose of folic
acid maybe up to 5.1mg in the trial arm (4.0mg from trial
medication and 1.1mg from routine supplementation) and up
to1.1mg in the placebo arm (from routine supplementation),
which is consistent with SOGC’s recommendation for high
risk pregnancy [38].
3.1. Inclusion Criteria. Nulliparous and multiparous women:
(1) ≥18 years of age at time of consent.
(2) Taking ≤1.1mg of folic acid supplementation daily at
the time of randomization.
(3) Live fetus.
(4) Gestational age between 80/7 and 166/7 weeks of
pregnancy (gestational age is based on the first day
of the last menstrual period or ultrasound performed
before 126/7).
(5) Planning to give birth in a participating hospital site.
(6) Presenting with at least one of the following identified
risk factors for PE:
(a) prepregnancy chronic hypertension (or dias-
tolic blood pressure≥90mmHgon two separate
occasions of at least 4 hours apart or use of
antihypertensive medication for the treatment
of hypertension);
(b) pre-pregnancy diabetes (type I or type II);
(c) twin pregnancy;
(d) history of PE in the previous pregnancy;
(e) BMI≥35 kg/m2 within 3months prior or during
the first trimester of current pregnancy.
3.2. Exclusion Criteria
(1) Women with known history or presence of clinically
significant disease or condition which would be a
contraindication to folic acid supplementation of up
to 5.1mg daily for the duration of pregnancy.
(2) Womenwho have knownmajor fetal anomaly or fetal
demise.
(3) Women who have a history of medical complications,
including renal disease with altered renal function,
epilepsy, cancer, or use of folic acid antagonists such
as valproic acid.
(4) Womenwho are using illicit drug or alcohol abuse (≥2
drinks per day) during current pregnancy.
(5) Women with a known hypersensitivity to folic acid.
(6) Women with a triplet or higher order of multiple
pregnancy.
(7) Women who have previously participated in this
study in a previous pregnancy.
Wewill not excludewomenwho are affected by a previous
NTD.These women will have a supplementation of folic acid
at 5mg daily as well. But for this indication, the supplemen-
tation will be discontinued at 12 weeks of gestation, while for
the prevention of PE we propose to supplement for the whole
pregnancy.
4. Randomization and Blinding
A permuted blocked randomization method stratified by
centre is used to allocate eligible participants. The random-
ization scheme is generated by an independent statistician
based upon instructions from the study statistician. The ran-
domization process consists of a computer-generated random
listing of the treatment allocations stratified by centre and in
variable permuted blocks of 4 and 6, due to the two groups
assignment. The Method Centre at the Ottawa Hospital
Research Institute has implemented randomization via the
web. To ensure compliance, the trial participants are provided
instruction for the appropriate use of study medication and
a study treatment diary. Pill counts and review of the study
treatment diary will provide data for teaching regarding
compliance at each study visit to optimize results.
Participants are being randomized in a 1 : 1 ratio to 4.0mg
folic acid and placebo. For the purposes of endpoint collec-
tion, the Trial Coordinating Center, data management team,
investigators, site personnel, and participants will remain
blinded to whether women received the folic acid or placebo
throughout the entire study.
Folic acid 4.0mg or placebo will be taken daily by oral
administration from randomization (80/7–166/7 weeks) until
delivery by the trial participant. We have a balanced con-
sideration on the starting date of the intervention. Ideally,
according to our hypothesis, an earlier intervention should
have a better effect. However, it would not be realistic
to recruit patients from participating centers earlier than
8 weeks of gestation. Both the folic acid and placebo have
identical external appearances to maintain masking, and
folic acid has no taste so the participants are not able
to determine if they have been allocated to the treatment
or placebo group. We expect that the folic acid from
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food intake and routine supplementation between trial arm
and placebo arm will be balanced through randomization.
However, we will collect information on additional sources
of folic acid in concomitant medications and a food fre-
quency questionnaire (Block Dietary Folate Equivalents
(DFE) Screener, http://www.nutritionquest.com/) and will
analyze these impacts on study results.
5. Followups
The study participants will have 5 study visits. First visit is
at recruitment between 80/7–166/7 weeks of gestation, second
visit at 240/7–266/7 weeks of gestation, third visit at 340/7–
366/7 weeks of gestation, fourth visit postpartum just after
delivery, and fifth visit as a telephone interview 42 ± 3 days
postpartum. If prenatal records are not included in the hospi-
tal records, the research team will contact the office of the
treating physician to obtain prenatal records.Data ondelivery
and neonatal status will be abstracted from hospital charts
after discharge. For participants who deliver in a centre other
than the one initially planned, the research team will contact
themedical center and obtain the delivery record to complete
data collection.
6. Primary and Secondary Outcome Measures
PE is the primary outcome measure. PE is defined as blood
pressure ≥90mmHg diastolic on two occasions ≥4 hours
apart and proteinuria greater than 2+ on dipstick or greater
than 300mg in 24-hour urine collection or random protein-
creatinine ratio ≥30mg protein/mmol, developed in women
greater than 20 weeks of gestation; or HELLP syndrome
(hemolysis, serum LDH ≥600U/L, serum AST ≥70U/L,
platelet count <100 × 109/L); or superimposed PE, defined as
history of preexisting hypertension (diagnosed prepregnancy
or before 20 weeks gestation) with new proteinuria. An adju-
dication committee comprised of experts in perinatology will
blindly adjudicate for the primary outcome.
Secondary outcomes include maternal death, severe PE
(PE with convulsion(s) or HELLP or delivery <34 weeks),
abruptio placenta, preterm delivery, premature rupture of
membranes, antenatal inpatient days, intrauterine growth
restriction, perinatal mortality, spontaneous abortion, still-
birth, neonatal death, and neonatal morbidity including
retinopathy of prematurity, periventricular leukomalacia,
early onset sepsis, necrotising enterocolitis, intraventricular
hemorrhage, ventilation, need for O
2
at 28 days, and length
of stay in neonatal intensive care unit (NICU).
7. Blood Pressure and
Proteinuria Measurements
On visits 1, 2, and 3, systolic and diastolic blood pressure
measurements will be measured in a standardized fashion by
trained members of the study team, the participants’ weight
will be obtained on a calibrated scale, and urine for proteinu-
ria will be evaluated by dipstick.
8. Sample Size and Power Estimation
Two-sided test is assumed in the sample size calculation.
Based on the literature [39], the best estimation of incidence
of PE in the high risk population is 12%. With an alpha error
of 5% and a power of >90%, 3,064 women (1,532 in each
group) are required to demonstrate a decrease of 30% in the
incidence of PE (from 12% to 8.4%) in the trial group (4.0mg
of folic acid) as compared with the placebo group [40]. We
will recruit 3,656 high risk women within the study period.
This will allow for noncompliance, withdrawn, loss to follow
up, and other unanticipated events. The power in our study
to detect 30% reduction of PE is 90%. Based on findings from
observational studies, all showed unanimously a 30% ormore
reduction in PE in the supplementation group, suggesting
that a 30% reduction in the trial arm as compared with
placebo arm is achievable. Moreover, a 30% reduction would
be considered clinically important.
We anticipate a rate of loss to follow up of <10%. This
estimate is a realistic estimate based on other trials that have
recruited high risk pregnant women in their first trimester
and followed to birth which had the same patient population,
outcome ascertainment, treatment mediation, and duration
and frequency of visits as the FACT study. Furthermore, these
women have existing medical complications of pregnancy
that require close management and allows for study visits to
be combined with antepartum visits with the high risk care
provider.
9. Data Analyses
The analysis will be carried out on an “intention to treat”
basis. We will first compare the difference in prognostic vari-
ables, compliance, and folic acid intake from other sources
between intervention and placebo groups. We will then
compare the outcomes between the intervention and placebo
groups andmake adjustment for prognostic and other factors
that might confound the comparison.
Chi-square test will be used in the comparison of inci-
dence of PE between the intervention and placebo groups.
Multiple logistic regression analysis will be used to adjust for
potential confounding by parity (0,≥1, 0 as the reference), age
(<20, 20–34, ≥35, 20–34 as the reference), cigarette smoking
(yes, no, no as the reference), and other important prognostic
factors identified at the description stage.
Chi-square test will be used in the comparison of the
occurrences of secondary outcome measures, and t-test will
be used in the comparison of means of birth weight and
gestational age, between the intervention and placebo groups.
Multiple logistic regression will be used for binary outcomes,
and multiple linear regression analysis will be used for
continuously distributed outcomes to adjust for confounding
by parity, age, cigarette smoking, and other important prog-
nostic factors.
Interim analysis will be performed by the independent
DSMB when one-half or 1,828 participants have been ran-
domized and visit 5 (postpartum telephone interview at
42 ± 3 days) has been completed to verify the study trial
assumptions. All adverse events will be collected from the
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time of randomization to visit 5 (postpartum telephone
interview at 42 ± 3 days), the last completed study visit. An
adverse event is defined as any untoward medical occurrence
in a patient or clinical investigation subject administered a
pharmaceutical product and which does not necessarily have
a causal relationship with the treatment in accordance with
GCP.
10. Results
The FACT study was funded by the Canadian Institutes
of Health Research in 2009, and regulatory approval from
Health Canada was obtained in 2010. We have worked
diligently to implement the FACT study in Canada and inter-
nationally. A summary of the progress is presented below.
(1) Development and finalization of all FACT related
documents including the study protocol, monitoring
plan, standard operating procedures, procedureman-
ual, and case report forms (CRFs).
(2) Receipt and PK testing of study treatment.
(3) Creation and implementation of an electronic web
randomization and EDCS.
(4) Identification and recruitment of clinical sites (21
Canadian sites, with 18 active sites up to June 15, 2013).
(5) Identification and recruitment of international col-
laborators (7 international collaborators in Australia,
Argentina, UK, Netherlands, West Indies, Brazil, and
the United States).
As of June 15, 2013, 450 participants have been random-
ized. Additional centers from Canada, Australia, Argentina,
UK, Netherlands, West Indies, Brazil, and the United States
will join our recruitment efforts soon.
11. Discussion
The health benefit of folic acid has so far been focused on
its effect on NTDs. Several observations on the association
between folic acid and NTDs have been made. Examples
include low folate intake levels and risk of NTDs was high
in pregnancies from low socio-economic families [41, 42],
mean RBC folate concentrations in women with a NTD was
lower [43], folic acidmetabolism in pregnant women affected
by NTD was impaired [44], and the use of aminopterin,
a powerful folic acid antagonist, was associated with anen-
cephaly [45]. These observations have led to large scale
randomized controlled trials of the effect of periconceptional
folic acid supplementation on preventing NTDs. The trials
demonstrated a dramatic effect of folic acid on NTDs, at least
70% reduction in the recurrence or first occurrence of NTDs
[46, 47]. Based on evidence from the randomized controlled
trials, policies and guidelines on periconceptional folic acid
supplementation have been implemented since the 1990s in
many countries including Canada [37, 38, 48], with high dose
folic acid (4.0–5.0mg) recommended for high risk women
and low dose folic acid (0.4–1.1mg) for low risk women in
the prevention of NTDs. High dose folic acid (5mg per day)
during pregnancy to treat anaemia in earlier clinical trials
[48, 49] did not show any effect on pregnancy complications,
a reassurance of its safety.The hypothesis behind the effect of
periconceptional folic acid supplementation on NTDs states
that once the chorioallantoic placenta is formed and the fetal
heart starts to perfuse it, the requirements for folic acid by
the conceptus increase steeply. Based on the fact that folate
is required for nucleotide synthesis and cellular methylation
potential and therefore modifies DNA synthesis, cell prolifer-
ation, and gene regulation, a shortage of folate at this stage
might interfere with the orderly closure of the neural tube
[50]. While this mechanismmay explain the observed effects
of folic acid on pregnancy outcomes other than NTDs, a
number of other mechanisms have been proposed to explain
the observed beneficial effect of folic acid supplementation
on PE (Figure 1). The first is related to placental implantation
and development. A well implanted and developed placenta
is essential for the health and wellbeing of the mother
and the fetus. Placental growth/development is a period of
increased cell proliferation and differentiation. Therefore,
higher folate intakes may be required to support appropriate
placental implantation and growth and development in early
pregnancy. The second is related to the effect of folic acid
on lowering blood homocysteine levels [51, 52], as hyperho-
mocysteinemia is a risk factor for a number of pregnancy
complications including PE [53–55].The third is related to the
effect of folate on improving systemic endothelial function
and therefore reducing the risk of such complications as PE
[55–58].
The potential impacts of folic acid on maternal and child
health beyond its effect on NTDs, combined with the lack
of solid scientific evidence on the association between folic
acid supplementation and adverse outcomes in mothers and
offspring, have created a dilemma in folic acid supplementa-
tion during pregnancy. The proposed 4.0mg folic acid sup-
plementation in the FACT study has been recommended for
womenwith a previous pregnancy complicated by anNTDby
the federal government of Canada [37].The recommendation
by SOGC [38] is even more liberal in terms of dosage (5.0mg
instead of 4.0mg) and of the targeted population (including
women with epilepsy or family history or high risk ethnic
group or women without obvious increased risk but with
poor supplementation compliance) for high dose supplemen-
tation. The SOGC has recently changed their recommenda-
tion, partly because of the lack of evidence; however, many
centers and physicians maintain their position on liberal use
of high dose folic acid supplementation for such indications
as diabetes and obesity throughout pregnancy (Dr. Mark
Walker, SIOGCChair, personal communication). If high dose
folic acid is truly beneficial and more conclusive evidence
of the benefit is not forthcoming, this treatment may not be
offered towomen at increased risk ofNTDs and other adverse
outcomes such as PE, thus denying future generations of
women and their offspring this potentially beneficial therapy.
On the other hand, if high dose folic acid supplementation
is not truly beneficial and more evidence concerning lack of
benefit is not forthcoming, practice may gradually change to
increase the dose of folic acid supplementation, particularly
because there are presently no other effective therapies to
offer. Should high dose of folic acid supplementation found to









Figure 1: Schematic of different proposed mechanisms of action by
which folic acid decreases the risk of developing preeclampsia.
be harmful, future generations of women and their offspring
may suffer needlessly. Studies that can offer definitive answers
to this important question are thus urgently needed.
Given the disease burden of PE, novel preventions, such
as folic acid, need to undergo proper scientific investigation.
The results obtained in the FACT trial will inform clini-
cal decision making by indicating whether daily supplemen-
tation with 4.0mg folic acid starting in early pregnancy (8 to
16 weeks of gestation) until delivery is effective in preventing
PE and its associated adverse outcomes in women with
increased risk of developing PE. Follow-up studies for study
participants in this large trial can provide answer to the ques-
tion whether folic acid supplementation during pregnancy
has impact on long-term outcomes in the mothers and their
offspring.
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